Unmet Needs in Respiratory Diseases
Identifieur interne : 000126 ( Istex/Corpus ); précédent : 000125; suivant : 000127Unmet Needs in Respiratory Diseases
Auteurs : Christopher ChangSource :
- Clinical Reviews in Allergy & Immunology [ 1080-0549 ] ; 2013-12-01.
English descriptors
- KwdEn :
- Anti-neutrophil cytoplasmic antibody, Biological modulators, Churg–Strauss syndrome, Cystic fibrosis, Cystic fibrosis transmembrane conductance receptor, Gene therapy, Granulomatosus with polyangiitis, Mycobacterium tuberculosis, Pertussis, Respiratory syncytial virus, Rhinovirus, Severe acute respiratory syndrome, Tuberculosis, Vaccination, Vaccines, Wegener’s granulomatosus.
Abstract
Abstract: The care of patients with respiratory diseases has improved vastly in the past 50 years. In spite of that, there are still massive challenges that have not been resolved. Although the incidence of tuberculosis has decreased in the developed world, it is still a significant public health problem in the rest of the world. There are still over 2 million deaths annually from tuberculosis, with most of these occurring in the developing world. Even with the development of new pharmaceuticals to treat tuberculosis, there is no indication that the disease will be eradicated. Respiratory syncytial virus, severe acute respiratory syndrome, and pertussis are other respiratory infectious diseases with special problems of their own, from vaccine development to vaccine coverage. Asthma, one of the most common chronic diseases in children, still accounts for significant mortality and morbidity, as well as high health care costs worldwide. Even in developed countries such as the USA, there are over 4,000 deaths per year. Severe asthma presents a special problem, but the question is whether there can be one treatment pathway for all patients with severe asthma. Severe asthma is a heterogeneous disease with many phenotypes and endotypes. The gene for cystic fibrosis was discovered over 24 years ago. The promise of gene therapy as a cure for the disease has fizzled out, and while new antimicrobials and other pharmaceuticals promise improved longevity and better quality of life, the average life span of a patient with cystic fibrosis is still at about 35 years. What are the prospects for gene therapy in the twenty-first century? Autoimmune diseases of the lung pose a different set of challenges, including the development of biomarkers to diagnose and monitor the disease and biological modulators to treat the disease.
Url:
DOI: 10.1007/s12016-013-8399-2
Links to Exploration step
ISTEX:991D0DE54A3031E2BBC85142F105776B30A8E6CFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Unmet Needs in Respiratory Diseases</title><author><name sortKey="Chang, Christopher" sort="Chang, Christopher" uniqKey="Chang C" first="Christopher" last="Chang">Christopher Chang</name><affiliation><mods:affiliation>Division of Allergy and Immunology, Thomas Jefferson University, 1600 Rockland Road, 19803, Wilmington, DE, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: c3chang@yahoo.com</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:991D0DE54A3031E2BBC85142F105776B30A8E6CF</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1007/s12016-013-8399-2</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-Q92M2L5C-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000126</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000126</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Unmet Needs in Respiratory Diseases</title><author><name sortKey="Chang, Christopher" sort="Chang, Christopher" uniqKey="Chang C" first="Christopher" last="Chang">Christopher Chang</name><affiliation><mods:affiliation>Division of Allergy and Immunology, Thomas Jefferson University, 1600 Rockland Road, 19803, Wilmington, DE, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: c3chang@yahoo.com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Reviews in Allergy & Immunology</title><title level="j" type="abbrev">Clinic Rev Allerg Immunol</title><idno type="ISSN">1080-0549</idno><idno type="eISSN">1559-0267</idno><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2013-12-01">2013-12-01</date><biblScope unit="volume">45</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="303">303</biblScope><biblScope unit="page" to="313">313</biblScope></imprint><idno type="ISSN">1080-0549</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1080-0549</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-neutrophil cytoplasmic antibody</term><term>Biological modulators</term><term>Churg–Strauss syndrome</term><term>Cystic fibrosis</term><term>Cystic fibrosis transmembrane conductance receptor</term><term>Gene therapy</term><term>Granulomatosus with polyangiitis</term><term>Mycobacterium tuberculosis</term><term>Pertussis</term><term>Respiratory syncytial virus</term><term>Rhinovirus</term><term>Severe acute respiratory syndrome</term><term>Tuberculosis</term><term>Vaccination</term><term>Vaccines</term><term>Wegener’s granulomatosus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The care of patients with respiratory diseases has improved vastly in the past 50 years. In spite of that, there are still massive challenges that have not been resolved. Although the incidence of tuberculosis has decreased in the developed world, it is still a significant public health problem in the rest of the world. There are still over 2 million deaths annually from tuberculosis, with most of these occurring in the developing world. Even with the development of new pharmaceuticals to treat tuberculosis, there is no indication that the disease will be eradicated. Respiratory syncytial virus, severe acute respiratory syndrome, and pertussis are other respiratory infectious diseases with special problems of their own, from vaccine development to vaccine coverage. Asthma, one of the most common chronic diseases in children, still accounts for significant mortality and morbidity, as well as high health care costs worldwide. Even in developed countries such as the USA, there are over 4,000 deaths per year. Severe asthma presents a special problem, but the question is whether there can be one treatment pathway for all patients with severe asthma. Severe asthma is a heterogeneous disease with many phenotypes and endotypes. The gene for cystic fibrosis was discovered over 24 years ago. The promise of gene therapy as a cure for the disease has fizzled out, and while new antimicrobials and other pharmaceuticals promise improved longevity and better quality of life, the average life span of a patient with cystic fibrosis is still at about 35 years. What are the prospects for gene therapy in the twenty-first century? Autoimmune diseases of the lung pose a different set of challenges, including the development of biomarkers to diagnose and monitor the disease and biological modulators to treat the disease.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Christopher Chang</name><affiliations><json:string>Division of Allergy and Immunology, Thomas Jefferson University, 1600 Rockland Road, 19803, Wilmington, DE, USA</json:string><json:string>E-mail: c3chang@yahoo.com</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Tuberculosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cystic fibrosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cystic fibrosis transmembrane conductance receptor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Respiratory syncytial virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Rhinovirus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pertussis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Severe acute respiratory syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Wegener’s granulomatosus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Churg–Strauss syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Granulomatosus with polyangiitis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Anti-neutrophil cytoplasmic antibody</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Mycobacterium tuberculosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Gene therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Vaccines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Vaccination</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Biological modulators</value></json:item></subject><articleId><json:string>8399</json:string><json:string>s12016-013-8399-2</json:string></articleId><arkIstex>ark:/67375/VQC-Q92M2L5C-K</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>ReviewPaper</json:string></originalGenre><abstract>Abstract: The care of patients with respiratory diseases has improved vastly in the past 50 years. In spite of that, there are still massive challenges that have not been resolved. Although the incidence of tuberculosis has decreased in the developed world, it is still a significant public health problem in the rest of the world. There are still over 2 million deaths annually from tuberculosis, with most of these occurring in the developing world. Even with the development of new pharmaceuticals to treat tuberculosis, there is no indication that the disease will be eradicated. Respiratory syncytial virus, severe acute respiratory syndrome, and pertussis are other respiratory infectious diseases with special problems of their own, from vaccine development to vaccine coverage. Asthma, one of the most common chronic diseases in children, still accounts for significant mortality and morbidity, as well as high health care costs worldwide. Even in developed countries such as the USA, there are over 4,000 deaths per year. Severe asthma presents a special problem, but the question is whether there can be one treatment pathway for all patients with severe asthma. Severe asthma is a heterogeneous disease with many phenotypes and endotypes. The gene for cystic fibrosis was discovered over 24 years ago. The promise of gene therapy as a cure for the disease has fizzled out, and while new antimicrobials and other pharmaceuticals promise improved longevity and better quality of life, the average life span of a patient with cystic fibrosis is still at about 35 years. What are the prospects for gene therapy in the twenty-first century? Autoimmune diseases of the lung pose a different set of challenges, including the development of biomarkers to diagnose and monitor the disease and biological modulators to treat the disease.</abstract><qualityIndicators><score>10</score><pdfWordCount>8443</pdfWordCount><pdfCharCount>52495</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>11</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>287</abstractWordCount><abstractCharCount>1838</abstractCharCount><keywordCount>16</keywordCount></qualityIndicators><title>Unmet Needs in Respiratory Diseases</title><genre><json:string>review-article</json:string></genre><host><title>Clinical Reviews in Allergy & Immunology</title><language><json:string>unknown</json:string></language><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><issn><json:string>1080-0549</json:string></issn><eissn><json:string>1559-0267</json:string></eissn><journalId><json:string>12016</json:string></journalId><volume>45</volume><issue>3</issue><pages><first>303</first><last>313</last></pages><genre><json:string>journal</json:string></genre><editor><json:item><name>M. Eric Gershwin</name></json:item></editor><subject><json:item><value>Medicine</value></json:item><json:item><value>Medicine & Public Health</value></json:item><json:item><value>Allergology</value></json:item><json:item><value>Immunology</value></json:item><json:item><value>Internal Medicine</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-Q92M2L5C-K</json:string></ark><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1007/s12016-013-8399-2</json:string></doi><id>991D0DE54A3031E2BBC85142F105776B30A8E6CF</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-Q92M2L5C-K/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-Q92M2L5C-K/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-Q92M2L5C-K/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Unmet Needs in Respiratory Diseases</title><title level="a" type="sub" xml:lang="en">“You Can’t Know Where You Are Going Until You Know Where You Have Been”—Anonymous</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><availability><licence><p>Springer Science+Business Media New York, 2013</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2013</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Unmet Needs in Respiratory Diseases</title><title level="a" type="sub" xml:lang="en">“You Can’t Know Where You Are Going Until You Know Where You Have Been”—Anonymous</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Christopher</forename><surname>Chang</surname></persName><email>c3chang@yahoo.com</email><affiliation>Division of Allergy and Immunology, Thomas Jefferson University, 1600 Rockland Road, 19803, Wilmington, DE, USA</affiliation></author><idno type="istex">991D0DE54A3031E2BBC85142F105776B30A8E6CF</idno><idno type="ark">ark:/67375/VQC-Q92M2L5C-K</idno><idno type="DOI">10.1007/s12016-013-8399-2</idno><idno type="article-id">8399</idno><idno type="article-id">s12016-013-8399-2</idno></analytic><monogr><title level="j">Clinical Reviews in Allergy & Immunology</title><title level="j" type="abbrev">Clinic Rev Allerg Immunol</title><idno type="pISSN">1080-0549</idno><idno type="eISSN">1559-0267</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">3</idno><idno type="volume-issue-count">3</idno><editor xml:id="book-author-0000"><persName><forename type="first">M. Eric</forename><surname>Gershwin</surname></persName></editor><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2013-12-01"></date><biblScope unit="volume">45</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="303">303</biblScope><biblScope unit="page" to="313">313</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2013</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The care of patients with respiratory diseases has improved vastly in the past 50 years. In spite of that, there are still massive challenges that have not been resolved. Although the incidence of tuberculosis has decreased in the developed world, it is still a significant public health problem in the rest of the world. There are still over 2 million deaths annually from tuberculosis, with most of these occurring in the developing world. Even with the development of new pharmaceuticals to treat tuberculosis, there is no indication that the disease will be eradicated. Respiratory syncytial virus, severe acute respiratory syndrome, and pertussis are other respiratory infectious diseases with special problems of their own, from vaccine development to vaccine coverage. Asthma, one of the most common chronic diseases in children, still accounts for significant mortality and morbidity, as well as high health care costs worldwide. Even in developed countries such as the USA, there are over 4,000 deaths per year. Severe asthma presents a special problem, but the question is whether there can be one treatment pathway for all patients with severe asthma. Severe asthma is a heterogeneous disease with many phenotypes and endotypes. The gene for cystic fibrosis was discovered over 24 years ago. The promise of gene therapy as a cure for the disease has fizzled out, and while new antimicrobials and other pharmaceuticals promise improved longevity and better quality of life, the average life span of a patient with cystic fibrosis is still at about 35 years. What are the prospects for gene therapy in the twenty-first century? Autoimmune diseases of the lung pose a different set of challenges, including the development of biomarkers to diagnose and monitor the disease and biological modulators to treat the disease.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Tuberculosis</term></item><item><term>Cystic fibrosis</term></item><item><term>Cystic fibrosis transmembrane conductance receptor</term></item><item><term>Respiratory syncytial virus</term></item><item><term>Rhinovirus</term></item><item><term>Pertussis</term></item><item><term>Severe acute respiratory syndrome</term></item><item><term>Wegener’s granulomatosus</term></item><item><term>Churg–Strauss syndrome</term></item><item><term>Granulomatosus with polyangiitis</term></item><item><term>Anti-neutrophil cytoplasmic antibody</term></item><item><term>Mycobacterium tuberculosis</term></item><item><term>Gene therapy</term></item><item><term>Vaccines</term></item><item><term>Vaccination</term></item><item><term>Biological modulators</term></item></list></keywords></textClass><textClass><keywords scheme="Journal-Subject-Collection"><list><label>SC11</label><item><term>Medicine</term></item></list></keywords></textClass><textClass><keywords scheme="Journal-Subject-Group"><list><label>SCH</label><item><term>Medicine & Public Health</term></item><label>SCH11009</label><item><term>Allergology</term></item><label>SCB14000</label><item><term>Immunology</term></item><label>SCH33002</label><item><term>Internal Medicine</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2013-12-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-Q92M2L5C-K/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer US</PublisherName><PublisherLocation>Boston</PublisherLocation><PublisherImprintName>Humana Press</PublisherImprintName><PublisherURL>http://www.springer-ny.com</PublisherURL></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>12016</JournalID><JournalDOI>10.1007/12016.1559-0267</JournalDOI><JournalPrintISSN>1080-0549</JournalPrintISSN><JournalElectronicISSN>1559-0267</JournalElectronicISSN><JournalTitle>Clinical Reviews in Allergy & Immunology</JournalTitle><JournalAbbreviatedTitle>Clinic Rev Allerg Immunol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Code="SCH" Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Code="SCH11009" Priority="1" Type="Secondary">Allergology</JournalSubject><JournalSubject Code="SCB14000" Priority="2" Type="Secondary">Immunology</JournalSubject><JournalSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</JournalSubject><SubjectCollection Code="SC11">Medicine</SubjectCollection></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>45</VolumeIDStart><VolumeIDEnd>45</VolumeIDEnd><VolumeIssueCount>3</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>3</IssueIDStart><IssueIDEnd>3</IssueIDEnd><IssueTitle Language="En">Unmet Needs in Pulmonary Disease</IssueTitle><IssueArticleCount>3</IssueArticleCount><IssueHistory><OnlineDate><Year>2013</Year><Month>12</Month><Day>7</Day></OnlineDate><PrintDate><Year>2013</Year><Month>12</Month><Day>6</Day></PrintDate><CoverDate><Year>2013</Year><Month>12</Month></CoverDate><PricelistYear>2013</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Springer Science+Business Media New York</CopyrightHolderName><CopyrightYear>2013</CopyrightYear></IssueCopyright></IssueInfo><IssueHeader><EditorGroup><Editor><EditorName DisplayOrder="Western"><GivenName>M. Eric</GivenName><FamilyName>Gershwin</FamilyName></EditorName></Editor></EditorGroup></IssueHeader><Article ID="s12016-013-8399-2" OutputMedium="All"><ArticleInfo ArticleType="ReviewPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>8399</ArticleID><ArticleDOI>10.1007/s12016-013-8399-2</ArticleDOI><ArticleSequenceNumber>1</ArticleSequenceNumber><ArticleTitle Language="En">Unmet Needs in Respiratory Diseases</ArticleTitle><ArticleSubTitle Language="En">“You Can’t Know Where You Are Going Until You Know Where You Have Been”—Anonymous</ArticleSubTitle><ArticleFirstPage>303</ArticleFirstPage><ArticleLastPage>313</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2013</Year><Month>11</Month><Day>8</Day></RegistrationDate><OnlineDate><Year>2013</Year><Month>11</Month><Day>30</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer Science+Business Media New York</CopyrightHolderName><CopyrightYear>2013</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Christopher</GivenName><FamilyName>Chang</FamilyName></AuthorName><Contact><Phone>+1-302-6514321</Phone><Fax>+1-302-6516558</Fax><Email>c3chang@yahoo.com</Email></Contact></Author><Affiliation ID="Aff1"><OrgDivision>Division of Allergy and Immunology</OrgDivision><OrgName>Thomas Jefferson University</OrgName><OrgAddress><Street>1600 Rockland Road</Street><City>Wilmington</City><State>DE</State><Postcode>19803</Postcode><Country Code="US">USA</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En" OutputMedium="All"><Heading>Abstract</Heading><Para>The care of patients with respiratory diseases has improved vastly in the past 50 years. In spite of that, there are still massive challenges that have not been resolved. Although the incidence of tuberculosis has decreased in the developed world, it is still a significant public health problem in the rest of the world. There are still over 2 million deaths annually from tuberculosis, with most of these occurring in the developing world. Even with the development of new pharmaceuticals to treat tuberculosis, there is no indication that the disease will be eradicated. Respiratory syncytial virus, severe acute respiratory syndrome, and pertussis are other respiratory infectious diseases with special problems of their own, from vaccine development to vaccine coverage. Asthma, one of the most common chronic diseases in children, still accounts for significant mortality and morbidity, as well as high health care costs worldwide. Even in developed countries such as the USA, there are over 4,000 deaths per year. Severe asthma presents a special problem, but the question is whether there can be one treatment pathway for all patients with severe asthma. Severe asthma is a heterogeneous disease with many phenotypes and endotypes. The gene for cystic fibrosis was discovered over 24 years ago. The promise of gene therapy as a cure for the disease has fizzled out, and while new antimicrobials and other pharmaceuticals promise improved longevity and better quality of life, the average life span of a patient with cystic fibrosis is still at about 35 years. What are the prospects for gene therapy in the twenty-first century? Autoimmune diseases of the lung pose a different set of challenges, including the development of biomarkers to diagnose and monitor the disease and biological modulators to treat the disease.</Para></Abstract><KeywordGroup Language="En" OutputMedium="All"><Heading>Keywords</Heading><Keyword>Tuberculosis</Keyword><Keyword>Cystic fibrosis</Keyword><Keyword>Cystic fibrosis transmembrane conductance receptor</Keyword><Keyword>Respiratory syncytial virus</Keyword><Keyword>Rhinovirus</Keyword><Keyword>Pertussis</Keyword><Keyword>Severe acute respiratory syndrome</Keyword><Keyword>Wegener’s granulomatosus</Keyword><Keyword>Churg–Strauss syndrome</Keyword><Keyword>Granulomatosus with polyangiitis</Keyword><Keyword>Anti-neutrophil cytoplasmic antibody</Keyword><Keyword>Mycobacterium tuberculosis</Keyword><Keyword>Gene therapy</Keyword><Keyword>Vaccines</Keyword><Keyword>Vaccination</Keyword><Keyword>Biological modulators</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Unmet Needs in Respiratory Diseases</title><subTitle>“You Can’t Know Where You Are Going Until You Know Where You Have Been”—Anonymous</subTitle></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Unmet Needs in Respiratory Diseases</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Christopher</namePart><namePart type="family">Chang</namePart><affiliation>Division of Allergy and Immunology, Thomas Jefferson University, 1600 Rockland Road, 19803, Wilmington, DE, USA</affiliation><affiliation>E-mail: c3chang@yahoo.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="ReviewPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Springer US; http://www.springer-ny.com</publisher><place><placeTerm type="text">Boston</placeTerm></place><dateIssued encoding="w3cdtf">2013-12-01</dateIssued><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: The care of patients with respiratory diseases has improved vastly in the past 50 years. In spite of that, there are still massive challenges that have not been resolved. Although the incidence of tuberculosis has decreased in the developed world, it is still a significant public health problem in the rest of the world. There are still over 2 million deaths annually from tuberculosis, with most of these occurring in the developing world. Even with the development of new pharmaceuticals to treat tuberculosis, there is no indication that the disease will be eradicated. Respiratory syncytial virus, severe acute respiratory syndrome, and pertussis are other respiratory infectious diseases with special problems of their own, from vaccine development to vaccine coverage. Asthma, one of the most common chronic diseases in children, still accounts for significant mortality and morbidity, as well as high health care costs worldwide. Even in developed countries such as the USA, there are over 4,000 deaths per year. Severe asthma presents a special problem, but the question is whether there can be one treatment pathway for all patients with severe asthma. Severe asthma is a heterogeneous disease with many phenotypes and endotypes. The gene for cystic fibrosis was discovered over 24 years ago. The promise of gene therapy as a cure for the disease has fizzled out, and while new antimicrobials and other pharmaceuticals promise improved longevity and better quality of life, the average life span of a patient with cystic fibrosis is still at about 35 years. What are the prospects for gene therapy in the twenty-first century? Autoimmune diseases of the lung pose a different set of challenges, including the development of biomarkers to diagnose and monitor the disease and biological modulators to treat the disease.</abstract><subject lang="en"><genre>Keywords</genre><topic>Tuberculosis</topic><topic>Cystic fibrosis</topic><topic>Cystic fibrosis transmembrane conductance receptor</topic><topic>Respiratory syncytial virus</topic><topic>Rhinovirus</topic><topic>Pertussis</topic><topic>Severe acute respiratory syndrome</topic><topic>Wegener’s granulomatosus</topic><topic>Churg–Strauss syndrome</topic><topic>Granulomatosus with polyangiitis</topic><topic>Anti-neutrophil cytoplasmic antibody</topic><topic>Mycobacterium tuberculosis</topic><topic>Gene therapy</topic><topic>Vaccines</topic><topic>Vaccination</topic><topic>Biological modulators</topic></subject><relatedItem type="host"><titleInfo><title>Clinical Reviews in Allergy & Immunology</title></titleInfo><titleInfo type="abbreviated"><title>Clinic Rev Allerg Immunol</title></titleInfo><name type="personal"><namePart type="given">M. Eric</namePart><namePart type="family">Gershwin</namePart><role><roleTerm type="text">editor</roleTerm></role></name><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2013-12-07</dateIssued><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><subject><genre>Journal-Subject-Collection</genre><topic authority="SpringerSubjectCodes" authorityURI="SC11">Medicine</topic></subject><subject><genre>Journal-Subject-Group</genre><topic authority="SpringerSubjectCodes" authorityURI="SCH">Medicine & Public Health</topic><topic authority="SpringerSubjectCodes" authorityURI="SCH11009">Allergology</topic><topic authority="SpringerSubjectCodes" authorityURI="SCB14000">Immunology</topic><topic authority="SpringerSubjectCodes" authorityURI="SCH33002">Internal Medicine</topic></subject><identifier type="ISSN">1080-0549</identifier><identifier type="eISSN">1559-0267</identifier><identifier type="JournalID">12016</identifier><identifier type="IssueArticleCount">3</identifier><identifier type="VolumeIssueCount">3</identifier><part><date>2013</date><detail type="issue"><title>Unmet Needs in Pulmonary Disease</title></detail><detail type="volume"><number>45</number><caption>vol.</caption></detail><detail type="issue"><number>3</number><caption>no.</caption></detail><extent unit="pages"><start>303</start><end>313</end></extent></part><recordInfo><recordOrigin>Springer Science+Business Media New York, 2013</recordOrigin></recordInfo></relatedItem><identifier type="istex">991D0DE54A3031E2BBC85142F105776B30A8E6CF</identifier><identifier type="ark">ark:/67375/VQC-Q92M2L5C-K</identifier><identifier type="DOI">10.1007/s12016-013-8399-2</identifier><identifier type="ArticleID">8399</identifier><identifier type="ArticleID">s12016-013-8399-2</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer Science+Business Media New York, 2013</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Springer Science+Business Media New York, 2013</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-Q92M2L5C-K/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000126 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000126 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:991D0DE54A3031E2BBC85142F105776B30A8E6CF
|texte= Unmet Needs in Respiratory Diseases
}}
| This area was generated with Dilib version V0.6.33. |  |